Is Pfizer's 5.7% Dividend Yield Worth the Risk?
Pfizer's 5.7% dividend yield stands out in the healthcare sector. The company's 436% payout ratio raises concerns about dividend sustainability.
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results
Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with t...
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become ...
Pfizer Stock Vs. AbbVie
Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, ver...
PFE or NVO: Which Is the Better Value Stock Right Now?
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Pfizer (PFE) and Novo Nordisk (NVO). But which of these two companies is the best option for those lookin...
Why Pfizer (PFE) Outpaced the Stock Market Today
In the most recent trading session, Pfizer (PFE) closed at $29.74, indicating a +1.11% shift from the previous trading day.
3 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade
W.P. Carey has adjusted well to the shrunken need for office space following the pandemic. AT&T is adding heaps of broadband subscribers and retaining its mobile internet subscribers.
A Few Years From Now, You'll Wish You Had Bought This Undervalued Stock
Pfizer has an attractive valuation due to two key factors. The drugmaker has multiple growth drivers in its lineup and potentially more in the pipeline.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Pfizer (PFE) closed at $28.39, indicating a +0.32% shift from the previous trading day.
Pfizer Inc. (PFE) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants...
3 Bargain-Priced Growth Stocks for Fall 2024
While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it has...
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
The Phase 2 trial was evaluating the vaccine called VLA15 following a second booster dose given one year after the first one.
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and safety data from...
2 Incredibly Cheap Growth Stocks to Buy Now
Stock market prices don't tell you everything, and that's certainly true with these businesses. Pfizer is paving the way to future growth, but investors might need to be patient.
Related Companies